E7386
E7386 is a pharmaceutical drug with 6 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
0
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 1Trial Status & Enrollment
66.7%
2 of 3 finished
33.3%
1 ended early
3
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Study of E7386 in Participants With Selected Advanced Neoplasms
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult Participants
Clinical Trials (6)
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Study of E7386 in Participants With Selected Advanced Neoplasms
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult Participants
A Food-Effect Study of E7386 in Healthy Participants
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6